EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS
|
|
- Edmund Grant
- 5 years ago
- Views:
Transcription
1 EXTENDED-SPECTRUM BETA-LACTAMASES EMERGING GRAM-NEGATIVE ORGANISMS David J. Feola, Pharm.D., Ph.D. Assistant Professor University of Kentucky College of Pharmacy
2 Disclosures Research Funding Pfizer
3 Objectives 1. Distinguish between the characteristics of ESBLs and other mechanisms of antimicrobial resistance, and understand their epidemiology and impact 2. Discuss the detection, reporting, infection control practices, and antimicrobial stewardship strategies to minimize the impact of ESBL-producing organisms 3. Review the treatment options for infections caused by ESBL-producing bacteria, with an emphasis upon what is known about the efficacy and clinical experience of each
4 Antimicrobial Resistance We have a problem Emergence of resistance Collateral damage Mechanism overview
5 Modern Healthcare, August 7, 2006, page 36 Protesting infections from MRSA
6 Hospital Acquired Infections State of Pennsylvania Heath Care Cost Containment Counsel Mortality Length of Stay Average Charge Readmission Rate Without infection 1.8% 4.9 days $37, % With HAI 9.4% 21.6 days $306, % Patients/consumers can use this report as an aid in making decisions about where to seek treatment PA Health Care Cost Containment Council, February
7 A Disturbing Trend Sulfa, BL, AG, Chloramphenicol TCN, MAC, Vanc, RIF, FQ, TMP No new classes. Modification of existing agents. LZD, DAP, TIG CPT; DAL; New Entities Limited PCN-resistant S. aureus MRSA VRE VISA in 7 states MDR Pseudomonas and Acinetobacter, metallo-beta-lactamases, carbapenemases LZD-R S. aureus VRSA Over half of companies END antimicrobial research and development
8 The Critical Balance Importance of appropriate empiric therapy Mortality increases when initial therapy is inappropriate Effect of broad-spectrum therapy on resistance Resistance increases when broad-spectrum agents are needed; Resistance has a negative impact on outcomes Collateral damage
9 Antimicrobial Use and Resistance Changes in use parallel changes in resistance Resistance higher in healthcare-associated infections Patients with resistant infections more likely to have received prior antimicrobials Hospital areas of highest resistance associated with highest antimicrobial use Increased duration of therapy increase likeliness of colonization with resistant organisms Shales DM et al. CID 1997;25:
10 Example: Oximinocephalosporins Cefotaxime, ceftazidime, ceftriaxone cause Extended-spectrum beta-lactamase production Selection of stably de-repressed isolates in SPACE bacteria Selection of VRE Contribution to MRSA emergence Increased cases of Clostridium difficile associated diarrhea/colitis Dancer SJ. J Antimicrobial Chemother 2001; 48:
11 Perilous Cycle: KPC Example Resistant Pathogen ESBL-producing E. coli, K. pneumo, SPACE KPC Antimicrobial Resistance ESBL production Carbapenemase development Infection Unknown pathogen ESBL-producing bacteria KPC-producing infection Antimicrobial Use Oximinocephalosporins Carbapenems?????
12 Selection for Resistant Strains Resistant Strains Rare Antimicrobial Exposure Resistant Strains Dominant
13 Emergence of Resistance Susceptible Bacteria Resistant Bacteria Resistance Gene Transfer New Resistant Bacteria
14 Mechanism Classes Mechanism Drug modification/degradation Decreased bacterial permeability Affected Agents β-lactams, FQ, AGL, TCN, macrolides, linezolid, clindamycin Sulfa, AGL, TCN, daptomycin, carbapenems Alteration of target site Efflux pumps β-lactams, FQ, TCN, vancomycin, linezolid, clindamycin, macrolides FQ, AGL, TCN, macrolides, carbapenems
15 ESBL Emerging Resistance Epidemiology New enzymes Patient impact Risk factors
16 β-lactamases More than 800 have been described More than 200 are ESBLs Classified by: Plasmid vs. chromosomally mediated Genes located on plasmids can spread Constitutive vs. inducible production Expression relates to β-lactam exposure Bush K. Clin Infect Dis ;32: Livermore DM. Clin Microbiol Inf ;14:S
17 β-lactam Hydrolysis Sites of β-lactamase Hydrolysis Dever LA et al. Arch Intern Med ;151:
18 TEM and SHV β-lactamases TEM-1, TEM-2, SHV-1 Most common plasmid-mediated β-lactamases in Gram-negative bacteria Drove the development of Extended-spectrum cephalosporins: resist hydrolysis β-lactamase inhibitors: protect parent β-lactam compound Carbapenems: enzymes cannot bind Livermore DM. Clin Microbiol Inf ;14:S Rice LB. Pharmacotherapy ;19:120S-128S. 128S.
19 TEM and SHV β-lactamases Extended spectrum beta-lactamases (ESBL) Mutants of classical enzymes Hydrolyze most extended-spectrum cephalosporins and aztreonam Carbapenems are spared Inhibited by clavulanic acid Organisms that produce ESBLs Klebsiella, E. coli, other Enterobacteriaceae and nonfermenting Gram-negative bacteria Livermore DM. Clin Microbiol Inf ;14:S Livermore DM et al. J Antimicrob Chemother. 2001;48(suppl):59-64.
20 Molecular Basis of ESBLs Amino acid position Ceftazidime Enzyme MIC (µg/ml) TEM-1 <0.12 Glu Arg Glu TEM Glu Ser Glu TEM Glu Ser Lys TEM-26 >256 Lys Ser Glu Modified from Rice LB. Pharmacotherapy ;19:120S-128S. 128S.
21 Emergence of CTX-M Enzymes Distribution of CTX-M-15-producing E. coli Pitout JD. Drugs. 2010;70:
22 Results of CTX-M Emergence Increasing spectrum and prevalence of resistance complicate management Fluoroquinolones and trimethoprim-sulfamethoxazole resistance limit outpatient options Extended-spectrum cephalosporin resistance limits options in the hospital Results Delays in appropriate therapy Higher costs Increased use of last resort antimicrobials Johnson JR, et al. Clin Infect Dis. 2010;51:
23 AmpC β-lactamases Different from ESBLs Not inhibited by β-lactamase inhibitors Differing susceptibilities Usually chromosomally encoded Generally confers resistance to First-, second-, and third-generation cephalosporins and aztreonam Broad-spectrum penicillins associated with β-lactamase inhibitors Pfaller MA, Segreti J. Clin Infect Dis. 2006;42(suppl 4):S153-S163. Jones RN. Diagn Microbiol Infect Dis. 1998;31:
24 Chromosomal, Inducible AmpCs Produced by the SPACE Bacteria Serratia marcescens Pseudomonas aeruginosa Acinetobacter species Citrobacter species Enterobacter species β-lactamase under the control of the ampc gene (turn on) and repressor gene (turn off) Mutation is loss of the repressor gene terminology is the isolate becomes stably de-repressed Bush, K. Clin Infect Dis 2001; 32:
25 Stable De-repression Selection During Therapy Resistant Strain Resistant Strain Rare Dominant Selection of stable derepressed mutants: susceptible when tested, then resistance 3 days later
26 Carbapenemases Two categories: serine β-lactamases and metallo-β-lactamases (MBL) Can be chromosomally encoded or plasmid encoded Bacteria that produce Pseudomonas aeruginosa Acinetobacter baumannii Klebsiella oxytoca Escherichia coli Enterobacter cloacae Serratia marcescens Klebsiella pneumoniae Citrobacter freundii Proteus mirabolis Livermore DM, Woodford N. Trends Microbiol. 2006;14: Bonomo RA, Szabo D. Clin Infect Dis. 2006;43(suppl 2):S49-S56.
27 KPC Carbapenemase Outbreak 602 K. pneumoniae isolates collected during a NYC, citywide surveillance study 45% had ESBLs Of the ESBL-producing isolates, 3.3% carried KPC-2 Two hospitals experienced the rapid spread of carbapenem-resistant isolates involving 58 patients Overall 14-day mortality in bacteremic patients was 47% Bratu S, et al. J Antimicrobial Chemother 2005;56:
28 Risk Factors and Significance Risk factors for KPC colonization Increasing severity of illness Prior fluoroquinolone, cephalosporin, carbapenem use ICU admission Spread among Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. reported Outcomes study, K. pneumoniae infection mortality KPC-producing: 32.1% Carbapenem susceptible: 9.9% Patel G, et al. Infect Control Hosp Epidemiol. 2008;29: Gasink LB, et al. Infect Control Hosp Epidemiol. 2009;30: Kwak YG, et al. Microb Drug Resist. 2005;11:
29 New ESBL Gene (bla NDM-1 ) Patient traveled from Sweden to India for surgical procedure Developed a decubital ulcer, returned to Sweden Treated with amox/clav, amikacin, and gatifloxacin K. pneumoniae isolated from urine culture ESBL-producing carbapenem resistant E. coli isolate from wound Producing the MBL, designated NF-NDM-1 Yong D, et al. Antimicrob Agents Chemother. 2009;53: Rolain JM, et al. Clin Microbiol Infect. 2010;16:
30 Clinical Outcome: Mortality K. pneumoniae ESBL Pos ESBL Neg Bacteremia 1 52% (n=48) 29% (n=99) P=0.007 A. baumannii Imipenem Resistant Imipenem Susceptible Bacteremia % (n=40) 27.5% (n=40) P<0.05 P. aeruginosa Multidrug Resistant Not Multidrug Resistant Bacteremia 3 21% (n=82) 12% (n=82) P=0.08 Enterobacter spp. Imipenem Resistant Imipenem Susceptible Multiple sources 4 11% (n=33) 3% (n=33) P= Tumbarello M, et al. Antimicrob Agents Chemother. 2006;50: Kwon KT, et al. J Antimicrob Chemother. 2007;59: Aloush V, et al. Antimicrob Agents Chemother. 2006;50: Marchaim D, et al. Antimicrob Agents Chemother. 2008;52:
31 ESBL Production and Outcomes Non-urinary tract isolates of Klebsiella, E. coli Length of stay 21 days vs. 11 days (P=0.006) Clinical success 48% vs. 86% (P=0.027) Lee, et al. Inf Cont Hosp Epi 2006;27:
32 ESBL Impact: Bacteremia Study Mortality contribution in Enterobacteriaceae bacteremia OR P-value ESBL Inappropriate therapy ESBL (inappropriate therapy excluded) Inappropriate therapy (ESBL excluded) <0.001 Marchaim D, et al. Antimicrob Agents Chemother. 2010;54:
33 Management of ESBL s Detection Reporting Infection control Stewardship
34 Laboratory Detection Problem No simple marker for presence of ESBL ESBLs give variable MICs to the extended-spectrum cephalosporins Revised breakpoint for resistance should predict ESBL production ( 16 µg/ml) Present susceptibility break points for ceftazidime (revised 2010) Susceptible < 4 mcg/ml Intermediate 8 mcg/ml Resistant > 16 mcg/ml Livermore DM. Clin Microbiol Inf ;14:S
35 Recommended ESBL Detection ESBL screening If MIC 2 µg/ml to ceftazidime, cefotaxime, or ceftriaxone, then must do an: ESBL confirmatory test 3 two-fold concentration decrease in an MIC for an antimicrobial agent tested in combination with clavulanic acid or > 5 mm increase in ceftazidime/clavulanic acid zone diameter CLSI no longer recommends for individual patient care, only for epidemiological evaluations
36 Laboratory Detection of ESBLs Etest ESBL Prescribing Information; AB Biodisk.
37 Lab Detection Enzyme Organism Examples Inhibitors Detection ESBL K. pneumoniae E. coli P. mirabilis Clavulanic acid Tazobactam Sulbactam Screen: 3 rd ceph Confirm: 3 rd ceph + clavulanate AmpC K. pneumoniae Cloxacillin Screen: R to cefoxitin (plasmid) E. coli Boronic acid Confirm: Cefotetan + boronic acid MBL KPC P. aeruginosa Acinetobacter spp K. pneumoniae E. coli Metal chelation Clavulanic acid Tazobactam Boronic acid Screen: R to carbapenem Confirm: Carbapenem + EDTA Screen: Ertapenem Confirm: Refer to reference lab Pitout JDD. Expert Rev Anti Infect. 2008;6:
38 Antimicrobial Stewardship Infection control plus antimicrobial management Appropriate antimicrobial selection, dosing, route, and duration System selection of antimicrobials that cause the System selection of antimicrobials that cause the least collateral damage MRSA ESBLs Clostridium difficille Stable derepression Metallo-beta-lactamases and other carbapenemases VRE
39 Active Core Strategies Prospective audit with intervention and feedback to reduce inappropriate antimicrobial use Formulary restriction and pre-authorization leading to reductions in antimicrobial use and cost NOTE neither of these strategies are mutually exclusive
40 Formulary Restriction: Example Grams per 1000 Patient Days Year Third-Generation Cephalosporins Cefepime Ceftazidime-Resistant K Pneumoniae % Ceftazidime-R Resistant K Pneumoniae e Isolates After initiation of formulary restriction Third-generation cephalosporins use decreased Cefepime use remained stable Rates of ceftazidime-resistant Klebsiella pneumoniae decreased Martin CA et al. Am J Health Syst Pharm. 2005;62:
41 Antimicrobial Treatment Timely Any delay in initiation potentially lethal Appropriate All isolated pathogens are susceptible to 1 of the administered antibiotics Consider policies that limit use of cephalosporins and fluoroquinolones Dose agents consistent with PK/PD parameters Timely streamlining based on clinical response and microbiological data Prompt discontinuation when practical
42 Treatment Duration Prolonged antibiotics courses have long been considered the solution to, instead of the cause of, resistance CDC Get Smart Website Complete the prescribed course of treatment, even if you are feeling better. Example: CAP Guidelines 2000: We are not aware of any controlled trials that have specifically addressed the question of how long pneumonia should be treated 2007: Patients with CAP should be treated for a minimum of 5 days, should be afebrile for 48-72h, and should have no more than 1 sign of CAP-associated clinical instability before discontinuation of therapy. Rice LB. CID 2008;46: (accessed Mar 29, 2011) Mandel LA et al. CID 2007;44(Suppl 2):S27-72.
43 Treatment of ESBL Producers Drugs of choice Outcomes data Susceptibilities Future directions
44 Treatment: ESBL-Producers No longer nosocomial infections only Carbapenems the treatment of choice for serious infections Resistance to other antimicrobials (eg, aminoglycosides, fluoroquinolones, trimethoprim, sulfonamides, tetracyclines, and chloramphenicol) often present in ESBL producers Potential for selection of carbapenem-resistant variants reported Hunter PA, et al. J Antimicrob Chemother. 2010;65(suppl 1):i3-i17. Pitout JDD. Drugs. 2010;70:
45 Treatment: ESBL-Producers Carbapenems: current drugs of choice for serious infections Cefepime: more stability but reports of treatment failures Resistance to other antimicrobials often present in ESBL producers Paterson DL, et al. CID 2004; 39: Marchaim D, et al. Antimicrob Agents Chemother. 2010;54:
46 Carbapenem Clinical Data K. pneumoniae bacteremia Prospective study, 12 hospitals over 2 years 85 ESBL-producing isolates Carbapenems significantly lowered 14-day mortality rate Enterobacteriaceae ventilator-associated pneumonia Prospective, 20 patients with ESBL-producing strains Ertapenem clinical success rate of 80% K. pneumoniae bloodstream infection Clinical case series 35 cases caused by TEM-52-producing strains Success: imipenem/cilastatin 80% vs. ciprofloxacin 28% Endimiani A et al. CID 2004;38(2): Bassetti M et al. JAC 2007;60(2):433-5 Paterson DL et al. CID 2004;39(1):31-7
47 Susceptibilities Agent Nonsusceptibility (%) Piperacillin/tazobactam 0-53 Amoxicillin/clavulanate Gentamicin 9-67 Tobramycin Amikacin 5-27 Ciprofloxacin Sulfamethoxazole-trimethoprim Nitrofurantoin 6-29 Fosfomycin 1-9 Tigecycline 0-1 Pitout JDD. Drugs 2010;70(3):
48 Cefepime Active against some ESBL producers RCT comparison of imipenem vs. cefepime Prospective, multicenter, nosocomial pneumonia in ICU Subgroup analysis, ESBL-producers Cefepime: 4 of 13 patients failed therapy Imipenem/cilastatin: 0 of 10 patients failed therapy All isolates tested susceptible to cefepime Zanetti G et al. AAC 2003;47(11): Ramphal R et al. CID 2006;42 Suppl 4:S164-72
49 β-lactam/inhibitor Combinations Several studies support their use to reduce incidence of ESBL-producing bacteria vs. cephalosporins Pip/tazo efficacy in a limited number of studies All infections, 48 cases, 21-day success rate of 28% ESBL-producing E. coli, 43 cases, lower mortality when receiving either pip/tazo or a carbapenem vs. a cephalosporin or fluoroquinolone (9% vs. 35%) Amox/clavulanate in 37 patients with cystitis Cure rate 84% Efficacy tied to MIC to the combination Tumbarello M et al. AAC 2006;50(2): Gavin PJ et al. AAC 2006;50(6): Rodriguez-Bano J et al. Arch Int Med 2008;168(17):
50 Tigecycline Excellent in vitro activity against ESBL-producing strains (especially CTX-M producers) Success shown in animal infection models Successful case studies of its use published Morosini MI et al. AAC 2006;50(8):2695-9
51 Other Agents Aminoglycosides ESBL producers often resistant CTX-M-15 often carries AGL-modifying enzyme E. coli and K. pneumoniae bacteremia study 36 infections caused by ESBL-producing strains 7 of 15 patients treated with AGL had sufficient response Fluoroquinolones High rates of resistance May be an option if strains test susceptible Kim YK et al. AAC 2002;46(5): Pitout JD. Expert Rev Infect Ther 2008;6(5):
52 Other Agents Fosfomycin, nitrofurantoin Limited data Restricted to use against urinary tract infections Temocillin, colistin In vitro activity Clinical data not available Combination therapy currently being studied Pitout JDD. Drugs. 2010;70:
53 Treatment: Carbapenemase Producers Data limited to case series Review of 15 papers, total of 55 patient cases Polymyxins Good only when used in synergy Polymyxin B + rifampin Polymyxin B + imipenem Tigecycline Majority of cases report positive outcomes Aminoglycosides Majority of cases report positive outcomes Hirsch EB et al. JAC 2010;65(6):
54 Conclusions Antimicrobial stewardship practices effective in limiting emergence and spread of ESBL-producing organisms Emergence associated with use of 3 rd generation cephalosporins, fluoroquinolones, and carbapenems Must spare the use of carbapenems when possible Treatment options limited dire need for clinical experience trials to be published
3/24/2014. Applying Principles of Antimicrobial Stewardship to Effective Patient Care
Applying Principles of Antimicrobial Stewardship to Effective Patient Care David J. Feola, Pharm.D., Ph.D. Associate Professor, Pharmacy Practice and Science University of Kentucky College of Pharmacy
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationPrevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationMichael Hombach*, Guido V. Bloemberg and Erik C. Böttger
J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationThe impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker
The impact of antimicrobial resistance on enteric infections in Vietnam Dr Stephen Baker sbaker@oucru.org Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Outline The impact of antimicrobial
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao
ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More information10/9/2012. Unprecedented success of antibiotics in 1960s. Infectious diseases are #1 cause of mortality worldwide
I have no conflicts of interest in relation to this program Whitney Jones, PharmD Antimicrobial Stewardship Pharmacist Vanderbilt University Medical Center October 25, 2012 Understand the epidemiology
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationBad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016
Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationMicrobiology Basics and Applications to Clinical Practice
Microbiology Basics and Applications to Clinical Practice LINDSEY CHILDS-KEAN, PHARMD, MPH, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF FLORIDA COLLEGE OF PHARMACY ST. PETERSBURG, FL Disclosures I
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationAntibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
More informationUsing Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and
Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and Health-Care Associated Infections Overall Goals & Objectives:
More informationAntimicrobial Stewardship:
Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationPreserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationAddressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum
Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD
More informationDr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center,
Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Hospital Authority NDM-1, which stands for New Delhi Metallo-beta-lactamase-1
More informationANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More information